Search research articles
Contact Us
Filters
Showing results (111-120 of 218) with videos related to
Page
of 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2015
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Cancer
|
July 19, 2011
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group
Todd M Cooper, Janet Franklin, Robert B Gerbing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2017
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Katherine Tarlock, Todd A Alonzo, Michael R Loken, et al.
Biorxiv : the Preprint Server for Biology
|
September 26, 2025
Quantifying HLA transcripts by genotype in chimeric mixtures at single-cell resolution
Sami B Kanaan, Jason G Underwood, Rula Green Gladden, et al.
Journal of Hematology & Oncology
|
October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Haematologica
|
September 9, 2017
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531
Andrew P Voigt, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Leukemia
|
June 10, 2022
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials
Mohammed O Gbadamosi, Vivek M Shastri, Abdelrahman H Elsayed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2024
Influence of Nucleophosmin (<i>NPM1</i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration
Claudia Tregnago, Maddalena Benetton, Rhonda E Ries, et al.
Blood Advances
|
May 12, 2026
Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity
John N Colgan, Jack H Peplinski, Yi-Cheng Wang, et al.
British Journal of Haematology
|
May 21, 2013
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group
Norman J Lacayo, Todd A Alonzo, Urte Gayko, et al.
Page
of 22
Search research articles
Search
Showing results (111-120 of 218) with videos related to
Sort By:
Page
of 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2015
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Cancer
|
July 19, 2011
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group
Todd M Cooper, Janet Franklin, Robert B Gerbing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2017
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Katherine Tarlock, Todd A Alonzo, Michael R Loken, et al.
Biorxiv : the Preprint Server for Biology
|
September 26, 2025
Quantifying HLA transcripts by genotype in chimeric mixtures at single-cell resolution
Sami B Kanaan, Jason G Underwood, Rula Green Gladden, et al.
Journal of Hematology & Oncology
|
October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Haematologica
|
September 9, 2017
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531
Andrew P Voigt, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Leukemia
|
June 10, 2022
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials
Mohammed O Gbadamosi, Vivek M Shastri, Abdelrahman H Elsayed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2024
Influence of Nucleophosmin (<i>NPM1</i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration
Claudia Tregnago, Maddalena Benetton, Rhonda E Ries, et al.
Blood Advances
|
May 12, 2026
Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity
John N Colgan, Jack H Peplinski, Yi-Cheng Wang, et al.
British Journal of Haematology
|
May 21, 2013
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group
Norman J Lacayo, Todd A Alonzo, Urte Gayko, et al.
Page
of 22